Precise Matching, Source Control, Regulatory Priority
Successful procurement starts with accurate supplier selection, and regulatory compliance serves as the fundamental benchmark for all decisions in the pharmaceutical industry. Among tens of thousands of chemical and pharmaceutical manufacturers in China, identifying reliable partners with international perspectives and full alignment with global regulatory standards is extremely challenging. Improper supplier selection may lead to project delays, cost overruns, severe quality incidents, and even registration failures or market recalls of pharmaceutical products in target markets.
As your trusted local partner, we recognize that regulatory risk represents the most critical hidden threat within pharmaceutical supply chains. Our supplier screening service goes far beyond simple price and capability comparison. We adopt a regulation-led and quality-centered systematic selection mechanism to build a solid compliance firewall at the initial stage of cooperation, ensuring that your China-based supply chain is safe, reliable and fully controllable from the source.
Full-Scale Qualified Resource Database: Regulation-Based Precise Screening
We maintain a large pre-qualified supplier resource database that functions as a dynamically updated compliance library tagged with complete regulatory qualifications, rather than a mere enterprise directory.
• In-depth qualification verification: We not only verify whether suppliers hold valid DMF, GMP, ISO 13485 and other core certifications, but also conduct thorough audits on certification authorities, approved scopes, validity periods and historical non-conformities identified in previous regulatory audits. For API manufacturers, we confirm whether their DMF filings are successfully accepted by FDA or EMA. For CMO/CDMO facilities, we verify that their GMP certifications fully cover the specific dosage forms of client products, including sterile preparations and high-potency pharmaceuticals.
• Regulatory history traceability: We trace suppliers’ official inspection records through public databases of NMPA, FDA, EMA and other global regulatory authorities. Any FDA 483 observations, import bans or unrectified non-conformities from domestic unannounced inspections will serve as absolute veto criteria in our supplier evaluation system.
• Professional categorized product portfolio: Our database covers the entire industrial chain including APIs, pharmaceutical excipients and primary packaging materials such as cold-form aluminum foils, pharmaceutical glass bottles and rubber stoppers. We conduct refined classification based on product attributes including high potency, high sensitization and sterility requirements, as well as suppliers’ professional technical strengths, enabling rapid matching with experienced and regulation-compliant partners for specific therapeutic areas.
Multi-Dimensional Supplier Profiling: Compliance Adaptability Evaluation Beyond Production Capacity
Our supplier evaluation prioritizes regulatory adaptability rather than merely production output. A manufacturing site with large capacity cannot be qualified if its quality management system fails to meet ICH Q7 or EU GMP Annex 1 requirements for sterile production. Our multi-dimensional profiling system accurately evaluates the regulatory matching degree between suppliers’ existing capabilities and your product development and production demands.
• Quality management system maturity assessment: We preliminarily evaluate whether suppliers’ QMS complies with ICH Q10 quality system principles, focusing on their operational proficiency in core quality modules including change control, deviation handling and CAPA management. A mature and stable QMS is the fundamental guarantee for sustained compliant production.
• Alignment between technical capabilities and regulatory standards: Based on your technical specifications, we verify whether suppliers’ process validation, cleaning validation and analytical method validation strictly follow international guidelines including ICH Q2 and ICH Q7. For sterile products, we comprehensively assess sterility assurance levels, media fill test data and environmental monitoring systems to ensure full compliance with stringent global regulatory requirements.
• Data integrity culture assessment: Data integrity remains the core focus of global regulatory inspections. During the screening phase, we adopt targeted questionnaires and preliminary communication to evaluate suppliers’ understanding and practical implementation of ALCOA+ principles, fundamentally eliminating potential risks of data manipulation and irregular documentation.
Comprehensive Due Diligence: Regulatory Compliance Health Check
Prior to formal business engagement, we conduct full-scale background due diligence as a comprehensive regulatory compliance health check for potential suppliers.
• Statutory qualification verification: We validate the authenticity and validity of official credentials including business licenses, pharmaceutical production permits and environmental discharge certificates through authoritative official channels, ensuring suppliers possess legitimate production and operation qualifications.
• IP and legal risk assessment: We investigate potential intellectual property disputes, environmental violations and major legal litigations to evaluate suppliers’ operational stability and prevent supply chain disruptions caused by internal corporate risks.
• Supply chain transparency review: For key starting materials and critical excipients, we require full upstream supply chain disclosure and conduct secondary supplier capability assessment to ensure end-to-end supply chain transparency and traceability in line with global regulatory supply chain security requirements.
Driven by this rigorous, regulation-centric supplier identification system, every partner we recommend delivers both technical feasibility and reliable regulatory compliance. We help you accurately select cost-effective, globally compliant suppliers amid the complex Chinese market landscape, laying a solid foundation for the security and sustainability of your global pharmaceutical supply chain.
